Primary Sjögren Syndrome
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
GalapagosGLPG3970
LFBCollection sheet
Clinical Trials (2)
Total enrollment: 131 patients across 2 trials
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)
Start: Jan 2021Est. completion: Dec 202131 patients
Phase 2Terminated
Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy
Start: Jan 2019Est. completion: Jan 2027100 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 131 patients
2 companies competing in this space